Pelvic insufficiency fractures affected nearly one-third after gynecologic IMRT
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
Radiographic brain injury occurred in 16% of children, all asymptomatic; every affected patient had received high-dose chemotherapy.
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
Estimated immune-cell dose predicted lymphocyte decline and was substantially lower with proton plans, particularly spot-scanning proton arc therapy.
Response-guided target reduction has the strongest evidence, while proton therapy and immunotherapy-based de-escalation remain less established.
FLASH preserved corneal thickness and collagen organization better than conventional irradiation at 10 and 15 Gy, but protection weakened at 20 Gy.
Clostridium, Anaerococcus US436 and Granulicatella elegans were associated with moderate-to-severe acute dermatitis during breast radiotherapy.
Response-guided target reduction and sequential chemoradiotherapy have the strongest evidence, while proton and immunotherapy-based approaches remain less established.
Whole-breast irradiation with 26 Gy in five fractions produced mainly grade 1 toxicity in 2,036 patients, including those receiving a boost.
After prostate and pelvic nodal SBRT, no grade ≥3 late GU or GI toxicity occurred among 101 patients with high-risk disease.
Lower pretreatment microvascular health was associated with more acute toxicity overall, while disease-specific performance was strongest in breast cancer.
Once-weekly prostate-and-pelvis SBRT reduced acute gastrointestinal toxicity versus conventional IMRT without significantly increasing genitourinary toxicity.
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Twice-weekly 28 Gy in 5 fractions produced no grade 3 or higher toxicity and 98.8% excellent-to-good cosmesis at 1 year.